SynthesisTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2013
IDH1 mutation is associated with improved overall survival in patients with glioblastoma: a meta-analysis.
Synthesis in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Molecular Biomarkers in Glioblastoma: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2022Pooled it
- Association of Telomerase Reverse Transcriptase Promoter Mutations with the Prognosis of Glioma Patients: a Meta-Analysis.Molecular neurobiology · 2016Pooled it
- Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas.Medicine · 2016Pooled it
- Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies.Oncotarget · 2015Pooled it
- Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis.Journal of neuro-oncology · 2015Pooled it
- IDH mutation and MGMT methylation status in glioblastoma and other gliomas patients: a Russian retrospective cohort study.Journal of the Egyptian National Cancer Institute · 2025Article
- Survival Analysis and Correlates with Molecular Epidemiology: 10-Year Retrospective Series of High-Grade Glioma in Pakistan.Journal of cancer & allied specialties · 2024Article
- Diagnostic Approaches to Adult-Type Diffuse Glial Tumors: Comparative Literature and Clinical Practice Study.Current oncology (Toronto, Ont.) · 2023Review
- PRMT1 driven PTX3 regulates ferritinophagy in glioma.Autophagy · 2023Article
- Characteristics, Patterns of Care and Predictive Geriatric Factors in Elderly Patients Treated for High-GradeCancers · 2022Article
- Article
- Ten-year survival in glioblastoma patient with neurofibromatosis type 1: illustrative case.Journal of neurosurgery. Case lessons · 2022Article
- Immunohistochemical Detection and Prognostic Significance of p53, Epidermal Growth Factor Receptor, Murine Double Minute 2, and Isocitrate Dehydrogenase 1 in Glioblastoma Multiforme Patients of Pakistan.Clinical Medicine Insights. Oncology · 2022Article
- Treatment Patterns and Outcomes Among Elderly Glioblastoma Patients in Riyadh, Saudi Arabia.OncoTargets and therapy · 2022Article
- Dissecting and analyzing the Subclonal Mutations Associated with Poor Prognosis in Diffuse Glioma.BioMed research international · 2022Article
- A Prognostic Model for Glioblastoma Patients Treated With Standard Therapy Based on a Prospective Cohort of Consecutive Non-Selected Patients From a Single Institution.Frontiers in oncology · 2021Article
- Valproic Acid Enhanced Temozolomide-Induced Anticancer Activity in Human Glioma Through the p53-PUMA Apoptosis Pathway.Frontiers in oncology · 2021Article
- Multimodal imaging-defined subregions in newly diagnosed glioblastoma: impact on overall survival.Neuro-oncology · 2019Article
- Clinically Actionable Insights into Initial and Matched Recurrent Glioblastomas to Inform Novel Treatment Approaches.Journal of oncology · 2019Article
- Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival.Journal of neuro-oncology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies proposed that isocitrate dehydrogenase 1 (IDH1) mutation was associated with improved survival in patients with glioblastoma, but those studies reported varying estimates and yielded inconclusive results. The purpose of the present study was to determine the effect of IDH1 mutation on the prognosis of patients with glioblastoma by performing a meta-analysis. Pubmed and Embase databases were searched for eligible studies. Studies reporting overall survival by IDH1 mutation in patients with glioblastoma were considered potentially eligible for the meta-analysis. For the quantitative aggregation of the survival results, the IDH mutation effect was measured by the pooled hazard ratio (HR) with its 95% confidence interval (95%CI). Nine studies with a total of 1,669 patients with glioblastoma were finally included into this meta-analysis. Overall, the IDH1 mutation was associated with improved survival in patients with glioblastoma (random effects model HR = 0.45, 95%CI 0.29-0.69, P < 0.001). Sensitivity analysis further showed that the pooled estimates were stable in this meta-analysis. Therefore, the findings from this meta-analysis suggest that IDH1 mutation is associated with improved overall survival in patients with glioblastoma.
Indexed as
Identifiers
23904262What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.